Background: Statins are the most commonly prescribed agents for hypercholesterolemia
because of their efficacy and tolerability. As the number of patients in need of statin therapy …

Although LDL cholesterol (LDL‐C) is associated with an increased risk of coronary heart
disease, other lipoproteins and their constituents, apolipoproteins, may play an important …

The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter
trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin across dose …

The introduction of the hydroxy methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors
(statins) in 1987 was a major advance in the prevention and treatment of cardiovascular …

Rosuvastatin, a new statin, has been shown to possess a number of advantageous
pharmacological properties, including enhanced HMG‐CoA reductase binding …

Purpose The objective was to systematically review clinical trial data on the effects of statins
on high-density lipoproteins (HDL) and to examine the possibility that this provides …

BACKGROUND: In a multinational trial (4522IL/0081), we assessed the effects of switching
to low doses of rosuvastatin from commonly used doses of atorvastatin, simvastatin, and …

The aim of this article is to examine the benefit-risk profile of rosuvastatin at doses of 10 to
40 mg. In dyslipidemic patients, rosuvastatin produced markedly greater reductions in low …

Background: Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitor
developed for the treatment of dyslipidemia. The results of clinical trials suggest that it is …

The third edition of this well-received text provides a state-of-the-art treatise on modern
clinical practice relating to hyperlipidaemia and lipoprotein disorders, conditions responsible …